Harga 2 Obat Rekomendasi Terbaru WHO untuk Pasien Covid-19, Tembus Jutaan Rupiah

Any Hidayati

Editor:

  • WHO merekomendasikan Actemra dan Kevzara untuk obat Covid-19.
  • Actemra dibandrol dengan harga Rp1.162.200 dan Rp5.710.600 tergantung dosis.
  • Kevzara belum resmi masuk Indonesia tapi di AS dipatok dengan harga sekitar Rp55 juta untuk dosis 150mg/1,14ml.

SKOR.id - Selasa (6/7/2021), Badan Kesehatan Dunia (WHO) merekomendasikan dua jenis obat radang sendi untuk pengobatan Covid-19.

Dilansir dari Reuters.com, obat yang dimaksud oleh WHO tersebut adalah Actemra dari Roche dan Kevzara dari Sanofi.

Kedua obat tersebut telah diuji WHO kepada 10.930 pasien Covid-19 kategori berat dan kritis yang mana pasien yang mendapat suntikan salah satu obat tersebut memiliki progres positif ketimbang yang hanya mendapat perawatan biasa.

Sebanyak 6.449 orang menggunakan salah satu obat radang sendi tersebut memiliki kemungkinan hidup lebih besar dari 4.481 orang lainnya hanya mendapat perawatan biasa selama 28 hari pengujian tersebut.

Dilansir dari Kompas.com, obat jenis Acterma dapat mengatasi badai sitokin atau respon berlebihan tubuh terhadap infeksi ketika terpapar Covid-19.

Sehingga kerusakan organ tubuh akibat badai sitokin saat terpapar Covid-19 dapat ditekan karena menurunkan beberapa penanda inflamasi atau peradangan.

Meskipun telah teruji klinis, Actemra dan Kevzara adalah obat radang sendi yang tergolong obat keras.

Sehingga obat tersebut harus mendapat pengawasan ketat dari dokter atau tenaga kesehatan selama proses pemulihan.

Badan pengawas obat dan makanan Amerika Serikat telah memberikan izin edar untuk dua jenis obat tersebut sejak pekan lalu.

Di Indonesia, baru Actemra yang telah resmi beredar di pasaran dan mendapat izin edar dari Badan Pengawas Obat dan Makanan (BPOM).

Actemra atau Tocilizumab dosis 400mg/20ml dijual dengan harga Rp5.710.600. Sedangkan, dosis 80mg/4ml dibandrol dengan harga Rp1.162.200.

Kevzara di Amerika Serikat dipatok dengan harga 3.827 dolar AS atau setara Rp55 juta untuk dosis 150mg/1,14ml.

Walaupun telah direkomendasikan oleh WHO, dua obat radang sendi tersebut mempunyai beberapa efek samping untuk pemakainya.

Dilansir dari KATADATA Indonesia, kedua obat tersebut memiliki efek samping antara lain, infeksi pernapasan, sakit kepala, tekanan darah tinggi, peningkatan enzim hati, dan alergi.

Ikuti juga InstagramFacebookYouTube, dan Twitter dari Skor Indonesia.

Berita Covid-19 Lainnya:

Mengenal Perbedaan Sinovac dan AstraZeneca, 2 Vaksin yang Dipakai di Indonesia

Catat, Hal yang Perlu Diperhatikan Sebelum dan Setelah Vaksinasi Covid-19

Source: KompasReutersKata Data

RELATED STORIES

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

Ada beberapa pemain asing NBA yang berstatus bintang namun absen di Olimpiade 2020 Tokyo karena negaranya tak lolos

3 Rekomendasi Olahraga saat Isolasi Mandiri dengan Gejala Ringan Covid-19

Demi menjaga diri dan lingkungan sekitar, masyarakat yang mengalami gejala ringan-sedang Covid-19 disarankan untuk melakukan isolasi mandiri.

Skor co creators network
RIGHT_ARROW
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
RIGHT_ARROW

THE LATEST

macau open '25

Badminton

Jadwal 2 Wakil Indonesia di Final Macau Open 2025, Sama-sama Ketemu Malaysia

Alwi Farhan dan Sabar/Reza berpeluang persembahkan gelar buat Indonesia di Macau Open 2025, Minggu (3/8/2025).

Teguh Kurniawan | 02 Aug, 19:08

Pebulu tangkis muda Indonesia Alwi Farhan

Badminton

Capai Final Macau Open 2025, Alwi Farhan Berharap Bawa Pulang Gelar

Pebulu tangkis Indonesia, Alwi Farhan, di ambang gelar juara BWF World Tour Super 300 perdana dalam kariernya.

Teguh Kurniawan | 02 Aug, 18:34

tim voli putri indonesia

Other Sports

Timnas Voli Putri Indonesia Dipastikan Gagal Juara Leg Pertama SEA V.League 2025

Kalah lagi lawan Thailand, Sabtu (2/8/2025), Timnas Voli Putri Indonesia tak mungkin lagi juara leg pertama SEA V.League 2025.

Teguh Kurniawan | 02 Aug, 16:56

Erick Thohir

National

Erick Thohir Apresiasi Dukungan Pemprov Jatim dalam Pengembangan Sepak Bola Daerah

Ketua Umum PSSI, Erick Thohir, menyambut baik kesiapan Pemprov Jawa Timur dalam menyukseskan Liga 3 dan Liga 4 musim depan.

Teguh Kurniawan | 02 Aug, 16:08

TNC 2025.

Liga TopSkor

Format 8 vs 8 di TNC U-12 2025, Beri Kesan Positif Bagi Para Pelatih SSB

Banyak kesan yang positif yang dirasakan para pelatih SSB karena di TNC U-12 2025 ini memainkan format pertandingan baru yakni 8 vs 8.

Nizar Galang | 02 Aug, 15:29

Persib Bandung vs Western Sydney Wanderers di Laga Uji Coba. (Grafis: Deni Sulaeman/Skor.id)

Liga 1

Gol Tunggal Wiliam Marcilio Bawa Persib Taklukkan Western Sydney Wanderers

Persib Bandung menandai peluncuran skuad musim 2025-2026 lewat kemenangan 1-0 atas Western Sydney Wanderers, Sabtu (2/8/2025).

Teguh Kurniawan | 02 Aug, 14:10

justin hubner - fortuna sittard

National

Dipercaya Jadi Starter, Justin Hubner Senang Lakoni Debut bersama Fortuna Sittard

Justin Hubner main 64 menit dalam kekalahan Fortuna Sittard dari Bayer Leverkusen di laga uji coba, Jumat (1/8/2025).

Teguh Kurniawan | 02 Aug, 13:25

Futsal Indonesia (Hendy Andika/Skor.id)

Futsal

FFI Bentuk Operator Liga Profesional dan Gulirkan PFL 2

Pembentukan Operator Liga Profesional adalah langkah penting untuk memastikan pengelolaan kompetisi berjalan secara profesional dan terstruktur.

Rais Adnan | 02 Aug, 12:40

sea v.league 2025 putri

Other Sports

SEA V.League 2025 Sektor Putri: Jadwal, Hasil, dan Klasemen

Jadwal, hasil, dan klasemen SEA V.League 2025 sektor putri yang terus diperbarui seiring berjalannya turnamen.

Teguh Kurniawan | 02 Aug, 12:09

Zlatan Ibrahimovic, pesepak bola Swedia yang bermain di Italia. (Deni Sulaeman/Skor.id)

World

Kunjungi Bali, Zlatan Ibrahimovic Jalani Ritual Melukat di Pura Tirta Empul

Zlatan Ibrahimovic membagikan momen saat mengunjungi Bali melalui akun Instagramnya.

Rais Adnan | 02 Aug, 11:58

Load More Articles